Shares of CIGNA Co. (NYSE:CI) have been assigned an average recommendation of “Buy” from the nineteen analysts that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation, fifteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $205.18.

Several equities analysts recently commented on the stock. ValuEngine upgraded shares of CIGNA from a “hold” rating to a “buy” rating in a research note on Sunday, December 31st. Goldman Sachs Group assumed coverage on shares of CIGNA in a research note on Wednesday, January 3rd. They issued a “neutral” rating and a $247.00 price target on the stock. BMO Capital Markets assumed coverage on shares of CIGNA in a research note on Monday, October 16th. They issued a “market perform” rating and a $210.00 price target on the stock. Morgan Stanley upped their price target on shares of CIGNA from $195.00 to $223.00 and gave the company an “overweight” rating in a research note on Friday, November 3rd. Finally, Citigroup upped their price target on shares of CIGNA from $198.00 to $231.00 and gave the company a “buy” rating in a research note on Friday, November 3rd.

Shares of CIGNA (NYSE:CI) traded down $0.70 during mid-day trading on Friday, hitting $219.66. 1,380,200 shares of the stock were exchanged, compared to its average volume of 1,185,725. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.39 and a current ratio of 0.39. The company has a market capitalization of $54,420.00, a price-to-earnings ratio of 24.06, a PEG ratio of 1.47 and a beta of 0.51. CIGNA has a twelve month low of $133.52 and a twelve month high of $221.13.

CIGNA (NYSE:CI) last announced its quarterly earnings data on Thursday, November 2nd. The health services provider reported $2.83 EPS for the quarter, topping the Zacks’ consensus estimate of $2.36 by $0.47. CIGNA had a net margin of 5.74% and a return on equity of 18.85%. The business had revenue of $10.38 billion for the quarter, compared to analyst estimates of $10.17 billion. During the same quarter in the previous year, the firm posted $1.94 earnings per share. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. equities analysts predict that CIGNA will post 10.34 EPS for the current year.

In related news, Director Jane E. Md Henney sold 400 shares of the firm’s stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $212.96, for a total value of $85,184.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Donna F. Zarcone sold 5,971 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $215.43, for a total transaction of $1,286,332.53. The disclosure for this sale can be found here. Insiders sold 69,556 shares of company stock valued at $14,160,975 in the last three months. Company insiders own 1.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Saratoga Research & Investment Management acquired a new stake in CIGNA during the 3rd quarter valued at approximately $112,000. Iguana Healthcare Management LLC increased its position in CIGNA by 51.4% during the 3rd quarter. Iguana Healthcare Management LLC now owns 26,500 shares of the health services provider’s stock valued at $4,954,000 after purchasing an additional 9,000 shares during the period. Sectoral Asset Management Inc increased its position in CIGNA by 194.1% during the 3rd quarter. Sectoral Asset Management Inc now owns 45,615 shares of the health services provider’s stock valued at $8,527,000 after purchasing an additional 30,105 shares during the period. Assenagon Asset Management S.A. increased its position in CIGNA by 54.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 22,058 shares of the health services provider’s stock valued at $4,124,000 after purchasing an additional 7,775 shares during the period. Finally, Toronto Dominion Bank increased its position in CIGNA by 10.3% during the 3rd quarter. Toronto Dominion Bank now owns 95,683 shares of the health services provider’s stock valued at $17,885,000 after purchasing an additional 8,943 shares during the period. Institutional investors and hedge funds own 87.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/19/cigna-co-ci-given-consensus-rating-of-buy-by-analysts.html.

About CIGNA

Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.

Analyst Recommendations for CIGNA (NYSE:CI)

Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.